Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Òscar Asensio De la Cruz"'
Autor:
Laura Valdesoiro-Navarrete, María Esther León, Marcos Rodríguez, Martina Indiveri, Roser Ayats, Helena Larramona, Miguel García González, Òscar Asensio De la Cruz, Montserrat Bosque García
Publikováno v:
Allergologia et Immunopathologia. 50:1-6
Background: In most cases, severe asthma in children has an allergic etiology, but allergen-specific immunotherapy (AIT) is contraindicated. Objective: This study aimed at analyzing the safety and efficacy of AIT in patients with severe asthma treate
Autor:
Helene de Vicente, Silvia Bertolo, Felix Ratjen, Alex Horsley, Pedro Mondéjar-López, Òscar Asensio de la Cruz
Publikováno v:
Mondéjar-lópez, P, Horsley, A, Ratjen, F, Bertolo, S, De Vicente, H & Asensio De La Cruz, Ò 2021, ' A multimodal approach to detect and monitor early lung disease in cystic fibrosis ', Expert review of respiratory medicine, pp. 1-12 . https://doi.org/10.1080/17476348.2021.1908131
Introduction: In the early stages, lung involvement in cystic fibrosis (CF) can be silent, with disease progression occurring in the absence of clinical symptoms. Irreversible airway damage is present in the early stages of disease; however, reliable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b59dc071f031975f126d22d27dd4ae8
https://www.tandfonline.com/doi/full/10.1080/17476348.2021.1908131
https://www.tandfonline.com/doi/full/10.1080/17476348.2021.1908131
Autor:
Mirella, Gaboli, Òscar Asensio, de la Cruz, María Isabel Barrio Gómez, de Agüero, Antonio, Moreno-Galdó, Guadalupe Pérez, Pérez, Manuel Sánchez-Solís, de Querol
Publikováno v:
Pediatric pulmonology. 49(5)
To achieve a consensus of opinion among an expert group of pediatric pulmonologists regarding the appropriateness of the off-label use of palivizumab for some pediatric patients with severe respiratory diseases.A two-round modified Delphi technique w
Publikováno v:
Anales de Pediatría, Vol 90, Iss 4, Pp 251.e1-251.e10 (2019)
Resumen: El diagnóstico de fibrosis quística (FQ) a través del cribado neonatal (CN) está bien establecido en muchos países y brinda la oportunidad de un diagnóstico y tratamiento temprano antes del desarrollo de daño estructural pulmonar irre
Externí odkaz:
https://doaj.org/article/a9988150f03540c18860e7f7977fc9ce
Autor:
Silvia Gartner, Pedro Mondéjar-López, Óscar Asensio de la Cruz, María José Alonso, Marina Álvarez, Anselmo Andrés Martín, María Isabel Barrio Gómez de Agüero, María Jesús Cabero Pérez, Pilar Caro Aguilera, María Cols Roig, Isidoro Cortell Aznar-Pérez, Jordi Costa Colomer, Isabel Delgado Pecellín, Amparo Escribano Montaner, Joan Figuerola Mulet, Gloria García Hernández, Pilar Guayarte, David Gil Ortega, David Gómez Pastrana, Adelaida Lamas Ferreiro, José Luis Marín Soria, Carlos Martín de Vicente, Martín Navarro Merino, Concepción Oliva Hernández, Javier Pérez Frías, Estela Pérez Ruiz, Sandra Rovira Amigo, Antonio Salcedo Posadas, Manuel Sánchez-Solís, Josep Sirvent Gómez, Carlos Vázquez Cordero, José Ramón Villa Asensi
Publikováno v:
Anales de Pediatría (English Edition), Vol 90, Iss 4, Pp 251.e1-251.e10 (2019)
Newborn screening (NBS) for cystic fibrosis (CF) is well-established in many countries and provides the opportunity for an early diagnosis and treatment before the development of irreversible structural lung damage.In 1999, Catalonia, Castilla-León,
Externí odkaz:
https://doaj.org/article/8dd249170a644c38af89ff7e0f733184